Biota, Inc. Receives $4.2 Million R&D Tax Credit
11/7/2012 8:46:38 AM
More...
|
Biota, Inc., Nabi Biopharmaceuticals (NABI) Amend Merger Terms; $54 Million Transaction Down to $27 Million
9/18/2012 6:59:03 AM
More...
|
Biota, Inc. Announces Inavir Achieves Primary Endpoint in Phase III Prevention Study
8/22/2012 9:12:57 AM
More...
|
Biota, Inc. Announces Royalties from Inavir(R) and Relenza(TM) for Q4 and F2011
8/1/2011 8:38:28 AM
More...
|
Biota, Inc. Announces Preliminary Phase III Prophylaxis Trial Results for CS-8959
6/27/2011 10:00:19 AM
More...
|
Biota, Inc. Obtains US$2.9M National Institutes of Health (NIH) Grant for the Development of Novel Antibacterial
6/10/2011 8:52:50 AM
More...
|
Biota, Inc. Announces Relenza Royalty for March 2011 Quarter
4/28/2011 8:56:11 AM
More...
|
Biota, Inc. Announces Relenza Royalty for March 2011 Quarter
4/28/2011 8:29:56 AM
More...
|
Biota, Inc. Announces Relenza September Quarter Royalty of $2.1 Million from GlaxoSmithKline (GSK)
10/22/2010 11:41:53 AM
More...
|
Biota, Inc.'s HCV Research Agreement With Boehringer Ingelheim Corporation Concludes
4/20/2010 3:31:01 PM
More...
|
|